Guangzhou Jiayue Pharmaceutical Technology

Guangzhou Jiayue Pharmaceutical Technology is an active Chinese pharmaceutical company focused on the research and development of innovative small molecule drugs. Its pipeline includes late-stage clinical assets such as sufenidone for idiopathic pulmonary fibrosis (Phase 3), ERAS‑0015 targeting RAS-driven cancers (Phase 2), WXFL10030390 targeting PI3Ks/mTOR in STK11-mutant cancer (Phase 2), and JYP‑0061 for autoimmune diseases including atopic dermatitis and neuromyelitis optica. The company has also entered into notable licensing deals with international partners such as Erasca. Clinical results are not yet published for pivotal trials.